IBD

DR. DOUGLAS WOLF APPOINTED TO CROHN'S AND COLITIS FOUNDATION'S NATIONAL BOARD OF TRUSTEES

Retrieved on: 
Donnerstag, Mai 9, 2024
Health care, Crohn's disease, Capsule endoscopy, Research, Ulcerative colitis, IBD, Inflammatory bowel disease, Colonoscopy, Disease, Commitment, Medical director, Pharmaceutical industry

ATLANTA, May 9, 2024 /PRNewswire/ -- Dr. Douglas Wolf, United Digestive physician and Medical Director for the Center for Crohn's Disease & Ulcerative Colitis, has been appointed to the National Board of Trustees of the Crohn's and Colitis Foundation, the leading nonprofit organization focused on research and patient support for inflammatory bowel disease (IBD).

Key Points: 
  • Dr. Wolf's career spans four decades, during which he has dedicated himself to advancing the understanding and treatment of IBD through clinical practice, research, and patient advocacy.
  • He has conducted extensive clinical research on various aspects of IBD, including diagnostic testing, colonoscopy and capsule endoscopy, and biologic, small molecule, and nutritional therapy.
  • "I am deeply humbled and honored to accept this appointment to the Crohn's and Colitis Foundation's National Board of Trustees," expressed Dr. Wolf.
  • "Throughout my career, I have witnessed firsthand the profound impact that inflammatory bowel disease can have on individuals and their families.

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
Donnerstag, Mai 9, 2024
Volunteering, FDA, Modulation, Ulcerative colitis, Solipsism syndrome, CDAI, Food, Risk, Molina Healthcare, NLRP3, Research and development, CAPS, Plasma, Webcast, Science, Administration, TYK2, IBD, Obesity, Week, SAD, European Medicines Agency, Patient, Treatment, Peripheral, EMA, Inflammation, CSF, Cardiovascular disease, Biomarker, MACE, G&A, SAN, UC, Pharmaceutical industry

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent pipeline and business progress.

Key Points: 
  • ET to discuss its first quarter 2024 financial results and provide a corporate update.
  • First Quarter 2024 Financial Results:
    Cash Position: Cash, cash equivalents and marketable securities were $302.6 million as of March 31, 2024.
  • Research and Development (R&D) expenses: R&D expenses were $33.7 million for the first quarter of 2024, compared to $35.4 million for the first quarter of 2023.
  • Net loss: Net loss was $38.6 million for the first quarter of 2024, compared to $38.9 million for the first quarter of 2023.

Arizona Digestive Health Expands Services with New Physicians in Scottsdale

Retrieved on: 
Donnerstag, Mai 9, 2024
FDA, Patient, Gastroenterology, Liver disease, Education minister, Cardiology, Communication, ADH, ICP, Ulcerative colitis, Retirement, IBD, Disease, Inflammatory bowel disease, Physician, Health, TigerConnect, UC, Medical device

Scottsdale, AZ, May 09, 2024 (GLOBE NEWSWIRE) -- Arizona Digestive Health is pleased to announce the addition of two respected physicians, Dr. Prabhakar Swaroop and Dr. Sirish Rao, to its Scottsdale location at 5111 N Scottsdale Road, Scottsdale, AZ .

Key Points: 
  • Scottsdale, AZ, May 09, 2024 (GLOBE NEWSWIRE) -- Arizona Digestive Health is pleased to announce the addition of two respected physicians, Dr. Prabhakar Swaroop and Dr. Sirish Rao, to its Scottsdale location at 5111 N Scottsdale Road, Scottsdale, AZ .
  • "We are excited to welcome Dr. Swaroop and Dr. Rao to our team at Arizona Digestive Health," says Dr. Parag Chokshi , president of Arizona Digestive Health.
  • “We want our patients to feel empowered.”
    Arizona Digestive Health in Scottsdale offers comprehensive gastroenterology services, including timely office and endoscopy appointments.
  • For more information or to schedule an appointment, visit Arizona Digestive Health - Scottsdale or call 602-254-6686 today.

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024

Retrieved on: 
Donnerstag, Mai 9, 2024
Pain, Inflammation, GPR35, JPY, NPJ, Schizophrenia, IBD, GPR52, GSK, Inflammatory bowel disease, Movement, Income tax, Operating cost, Medicine, G&A, Growth, EP4, Pharmaceutical industry

Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2024.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2024.
  • R&D expenses totalled JPY 3,163 million (US$21.3 million), an increase of JPY 1,206 million (US$6.5 million) vs. the prior corresponding period.
  • G&A expenses totalled JPY 3,650 million (US$24.6 million), an increase of JPY 2,541 million (US$16.2 million) vs. the prior corresponding period.
  • Cash and cash equivalents as at 31 March 2024 amounted to JPY 46,515 million (US$307.3 million) having decreased by JPY 2,550 million (US$40.6 million) from the beginning of the year.

Denver Digestive Health Specialists Expands Into Arvada

Retrieved on: 
Montag, Mai 6, 2024
CO, FDA, Patient, DDHS, Vedolizumab, Travel, Health, DRS, Ulcerative colitis, IBD, GI, Inflammatory bowel disease, Physician, UC, Nursing

Arvada, CO, May 06, 2024 (GLOBE NEWSWIRE) -- Denver Digestive Health Specialists, the premier gastroenterology practice in Denver, has opened  a new gastro clinic in Arvada, located at 9950 West 80th Avenue.

Key Points: 
  • Arvada, CO, May 06, 2024 (GLOBE NEWSWIRE) -- Denver Digestive Health Specialists, the premier gastroenterology practice in Denver, has opened  a new gastro clinic in Arvada, located at 9950 West 80th Avenue.
  • DDHS is a proud partner of GI Alliance , the leading physician-owned and -led network of gastroenterology practices in the U.S.
    Dr. Jonathan Scott heads up Denver Digestive Health’s Arvada location to expand services and offer geographic convenience to patients.
  • Denver Digestive Health Specialists aims to alleviate these challenges for patients so they can receive the quality medical care they deserve.
  • “Taking into account such factors as the patient’s concerns, lifestyle and medical history, I map out a strategy for my patients to achieve the most optimal medical outcome possible.”
    Denver Digestive Health Specialists in Arvada and Denver are now accepting appointments for new patients.

Low-Dose Naltrexone in Gastroenterology: A Bonafide ‘Wonder Drug’

Retrieved on: 
Freitag, Mai 3, 2024
Defecation, Irritable bowel syndrome, Ulcerative colitis, Inflammation, Gastroenterology, Crohn's disease, RLS, Restless legs syndrome, Research, IBD, Inflammatory bowel disease, Flatulence, Psoriasis, Health, Immune system, LDN, IBS, Medical device

Dr. Weinstock's insightful piece sheds light on the potential of LDN as a novel therapeutic approach in the field of gastroenterology.

Key Points: 
  • Dr. Weinstock's insightful piece sheds light on the potential of LDN as a novel therapeutic approach in the field of gastroenterology.
  • Low-dose naltrexone, traditionally known for its role in managing opioid and alcohol dependence, has emerged as a compelling option for addressing various gastrointestinal conditions.
  • Furthermore, Dr. Weinstock highlights the need for further research and clinical trials to fully elucidate LDN's therapeutic potential in gastroenterology.
  • For more information on Dr. Leonard Weinstock's insights into low-dose naltrexone in gastroenterology, please read his full article here .

Sanctuary Wealth Redefines RIA Channel and Fully Supported Independence Model with Acquisition of tru Independence

Retrieved on: 
Mittwoch, Mai 1, 2024
Tru, Ecosystem, KPMG, RIAS, Freedom, Growth, RIA, Culture, IBD, Acquisition, Control, Financial adviser

INDIANAPOLIS, May 1, 2024 /PRNewswire/ -- Sanctuary Wealth (Sanctuary), home to the next generation of the industry's most elite financial advisors, today announced the acquisition of tru Independence (tru), a Portland, Oregon-based enterprise that supports 30 RIA firms managing $12.5 billion in client assets. The combination of Sanctuary and tru – each a top firm that has had a transformative impact within the fast-growing RIA channel – redefines independence in the wealth management space. Creating an unparalleled platform for highly sophisticated financial advisors, the combined enterprise offers the broadest possible range of independent business model affiliation options and capabilities across the industry landscape.

Key Points: 
  • The combination of Sanctuary and tru – each a top firm that has had a transformative impact within the fast-growing RIA channel – redefines independence in the wealth management space.
  • "Sanctuary and tru have built their businesses on partnered independence, where being independent does not mean going it alone.
  • tru is a pioneer in independent wealth management and an innovator in supporting elite advisors who wish to own their own RIAs.
  • "Sanctuary is the undisputed leader in helping top wirehouse advisors establish their independence with their multi-custody, corporate RIA model.

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

Retrieved on: 
Donnerstag, April 25, 2024
Political moderate, Inflammation, International, M1, WHO, Notifiable disease, USAN, Liver disease, Homeostasis, Chronic obstructive pulmonary disease, World Health Organization, Randomness, Monocyte, CVD, Drug development, Sepsis, DNA methylation, Microglia, Doctor of Philosophy, Dementia, Respiratory disease, Disease, IBD, INN, DNA, CKD, Exercise, Data, Inflammatory bowel disease, Diet, Patient, Macrophage, Metabolism, Cardiovascular disease, Jools' Annual Hootenanny, PD, Cancer, Chronic kidney disease, Gene, COPD, Vaccine

The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.

Key Points: 
  • The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.
  • But these data provide evidence that bezisterim may have the potential to help keep people healthier for a longer time as we age,” said Cuong Do, BioVie’s President and CEO.
  • “BioVie believes that DNA methylation may not need to constantly increase as we age, and thus the progression of age-related disease may not be uni-directional.
  • This suggests that bezisterim disrupted the negative consequences of DNA methylation that promotes inflammation and restored homeostasis.

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Retrieved on: 
Dienstag, April 23, 2024
Ulcerative colitis, Cancer, Inflammation, Poster, Colitis, Journal, Disease, IBD, GI, AAI, Treatment, Conditional, Therapy, Autoimmunity, UC, Pharmaceutical industry

WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced a poster presenting preclinical data characterizing conditionally-activated IL-10 INDUKINE molecules for the treatment of colitis in animal models, a novel approach leveraging its PREDATOR™ protein engineering platform, at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.

Key Points: 
  • Prolonged inflammation results in damage to the GI tract.
  • While the exact cause of IBD is unknown, autoimmune and immune-mediated factors have been shown to contribute to the severity of the disease.
  • Results highlighting Werewolf’s findings are summarized in a poster titled, “Development of Conditionally Active IL-10 INDUKINETM Molecules for the Treatment of Inflammatory Bowel Disease” (Board #B906).
  • The poster can be viewed in person on Monday, May 6, 2024, on board number B906, with Werewolf delegates present from 2:15-3:30pm to answer questions.

Dr. Bhavin Patel Joins DHAT in Bedford

Retrieved on: 
Montag, April 22, 2024
Richmond University Medical Center, American College, Liver disease, Communication, Cancer, IBD, Fecal incontinence, Patient, Health, Internal medicine, Esophageal dysphagia, IBS, Nursing

Dr. Patel is an experienced gastroenterologist affiliated with the American College of Gastroenterology, American Board of Internal Medicine, and many more.

Key Points: 
  • Dr. Patel is an experienced gastroenterologist affiliated with the American College of Gastroenterology, American Board of Internal Medicine, and many more.
  • He received his doctorate from Windsor University School of Medicine and completed his residency at Richmond University Medical Center.
  • “My patients can expect a patient-centered approach focused on providing personalized care,” says Dr. Patel.
  • DHAT is at 1600 Central Drive in Bedford, TX , and is open Monday through Friday, 8am to 5pm.